Berger Financial Group Inc Buys 415 Shares of Gilead Sciences, Inc. $GILD

Berger Financial Group Inc lifted its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.7% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 61,701 shares of the biopharmaceutical company’s stock after purchasing an additional 415 shares during the quarter. Berger Financial Group Inc’s holdings in Gilead Sciences were worth $6,841,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. BridgePort Financial Solutions LLC grew its holdings in Gilead Sciences by 71.0% during the 2nd quarter. BridgePort Financial Solutions LLC now owns 7,054 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 2,928 shares in the last quarter. Clarius Group LLC grew its holdings in shares of Gilead Sciences by 5.4% in the second quarter. Clarius Group LLC now owns 8,753 shares of the biopharmaceutical company’s stock valued at $970,000 after purchasing an additional 445 shares in the last quarter. AMF Tjanstepension AB increased its position in Gilead Sciences by 41.7% in the second quarter. AMF Tjanstepension AB now owns 524,960 shares of the biopharmaceutical company’s stock worth $58,244,000 after purchasing an additional 154,530 shares during the last quarter. LGT Fund Management Co Ltd. raised its stake in Gilead Sciences by 14.0% during the second quarter. LGT Fund Management Co Ltd. now owns 28,135 shares of the biopharmaceutical company’s stock valued at $3,119,000 after purchasing an additional 3,450 shares in the last quarter. Finally, Quent Capital LLC lifted its position in Gilead Sciences by 32.4% during the second quarter. Quent Capital LLC now owns 3,759 shares of the biopharmaceutical company’s stock valued at $417,000 after purchasing an additional 919 shares during the last quarter. 83.67% of the stock is owned by institutional investors.

Gilead Sciences Stock Up 1.9%

NASDAQ:GILD opened at $112.69 on Friday. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. Gilead Sciences, Inc. has a 1-year low of $83.98 and a 1-year high of $121.83. The company has a 50-day moving average of $114.34 and a 200 day moving average of $109.94. The firm has a market cap of $139.83 billion, a PE ratio of 22.45, a price-to-earnings-growth ratio of 0.77 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. During the same quarter in the previous year, the business posted $2.01 EPS. The company’s quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio (DPR) is 62.95%.

Insider Buying and Selling at Gilead Sciences

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer directly owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. The trade was a 1.54% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the sale, the insider owned 113,193 shares of the company’s stock, valued at $12,855,329.01. This trade represents a 2.58% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 82,000 shares of company stock valued at $9,402,130. 0.27% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on GILD shares. Daiwa America upgraded shares of Gilead Sciences from a “hold” rating to a “strong-buy” rating in a report on Tuesday, August 19th. Needham & Company LLC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and set a $133.00 price target for the company in a research report on Friday, July 25th. Rothschild & Co Redburn upped their price objective on Gilead Sciences from $136.00 to $143.00 and gave the company a “buy” rating in a research report on Friday, September 12th. UBS Group lifted their target price on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a report on Friday, August 8th. Finally, Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and a consensus target price of $117.17.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.